Attia Evelyn, Schroeder Laura
Columbia University and New York State Psychiatric Institute, New York, New York 10032, USA.
Int J Eat Disord. 2005;37 Suppl:S60-3; discussion S87-9. doi: 10.1002/eat.20133.
Anorexia nervosa (AN) is a serious mental disorder, characterized by severely low weight and cognitive distortions about body shape and weight. AN is generally associated with a range of psychological symptoms, including depression, anxiety, obsessions, and rituals. The current study summarized findings from randomized controlled trials (RCT) using pharmacologic treatments in patients with AN. We conducted a review of literature using Medline. Several classes of pharmacologic agents have been studied in small samples of patients with acute AN without finding clear benefit to eating, weight, body shape concerns, or associated psychopathology. Studies have been limited by small sample sizes, as well as by research design with most studies adding medication to comprehensive hospital-based treatment programs. Future directions for pharmacologic treatment research in AN should include outpatient trials, rigorous study of atypical antipsychotic medication, and assessment of medication effect for relapse prevention in weight-restored patients.
神经性厌食症(AN)是一种严重的精神障碍,其特征是体重严重偏低以及对体型和体重存在认知扭曲。神经性厌食症通常与一系列心理症状相关,包括抑郁、焦虑、强迫观念和仪式行为。本研究总结了在神经性厌食症患者中使用药物治疗的随机对照试验(RCT)的结果。我们使用Medline对文献进行了综述。在少量急性神经性厌食症患者样本中对几类药物进行了研究,但未发现对饮食、体重、体型担忧或相关精神病理学有明显益处。研究受到样本量小以及研究设计的限制,大多数研究是将药物添加到基于医院的综合治疗方案中。神经性厌食症药物治疗研究的未来方向应包括门诊试验、对非典型抗精神病药物的严格研究,以及评估药物对体重恢复患者预防复发的效果。